Relative hazards of reaching the endpoints by univariate and multivariate Cox analyses
| Outcomes . | Unadjusted and adjusted relative hazards . | |||
|---|---|---|---|---|
| unadjusted relative hazard (95% CI) . | P . | adjusteda relative hazard (95% CI) . | P . | |
| Treatment failure | ||||
| raltegravir based | 2.03 (1.36–3.03) | <0.001 | 2.00 (1.24–3.21) | 0.004 |
| dolutegravir based | 1.00 | 1.00 | ||
| elvitegravir/cobicistat based | 1.61 (1.12–2.31) | 0.011 | 1.88 (1.20–2.95) | 0.006 |
| Discontinuation due to toxicity | ||||
| raltegravir based | 1.33 (0.66–2.68) | 0.419 | 1.55 (0.69–3.50) | 0.286 |
| dolutegravir based | 1.00 | 1.00 | ||
| elvitegravir/cobicistat based | 1.43 (0.87–2.34) | 0.154 | 1.94 (1.00–3.76) | 0.051 |
| Outcomes . | Unadjusted and adjusted relative hazards . | |||
|---|---|---|---|---|
| unadjusted relative hazard (95% CI) . | P . | adjusteda relative hazard (95% CI) . | P . | |
| Treatment failure | ||||
| raltegravir based | 2.03 (1.36–3.03) | <0.001 | 2.00 (1.24–3.21) | 0.004 |
| dolutegravir based | 1.00 | 1.00 | ||
| elvitegravir/cobicistat based | 1.61 (1.12–2.31) | 0.011 | 1.88 (1.20–2.95) | 0.006 |
| Discontinuation due to toxicity | ||||
| raltegravir based | 1.33 (0.66–2.68) | 0.419 | 1.55 (0.69–3.50) | 0.286 |
| dolutegravir based | 1.00 | 1.00 | ||
| elvitegravir/cobicistat based | 1.43 (0.87–2.34) | 0.154 | 1.94 (1.00–3.76) | 0.051 |
Adjusted for age, gender, nation of birth, mode of HIV transmission, hepatitis coinfection status, AIDS diagnosis, baseline CD4 count, VL and year of starting cART.
Relative hazards of reaching the endpoints by univariate and multivariate Cox analyses
| Outcomes . | Unadjusted and adjusted relative hazards . | |||
|---|---|---|---|---|
| unadjusted relative hazard (95% CI) . | P . | adjusteda relative hazard (95% CI) . | P . | |
| Treatment failure | ||||
| raltegravir based | 2.03 (1.36–3.03) | <0.001 | 2.00 (1.24–3.21) | 0.004 |
| dolutegravir based | 1.00 | 1.00 | ||
| elvitegravir/cobicistat based | 1.61 (1.12–2.31) | 0.011 | 1.88 (1.20–2.95) | 0.006 |
| Discontinuation due to toxicity | ||||
| raltegravir based | 1.33 (0.66–2.68) | 0.419 | 1.55 (0.69–3.50) | 0.286 |
| dolutegravir based | 1.00 | 1.00 | ||
| elvitegravir/cobicistat based | 1.43 (0.87–2.34) | 0.154 | 1.94 (1.00–3.76) | 0.051 |
| Outcomes . | Unadjusted and adjusted relative hazards . | |||
|---|---|---|---|---|
| unadjusted relative hazard (95% CI) . | P . | adjusteda relative hazard (95% CI) . | P . | |
| Treatment failure | ||||
| raltegravir based | 2.03 (1.36–3.03) | <0.001 | 2.00 (1.24–3.21) | 0.004 |
| dolutegravir based | 1.00 | 1.00 | ||
| elvitegravir/cobicistat based | 1.61 (1.12–2.31) | 0.011 | 1.88 (1.20–2.95) | 0.006 |
| Discontinuation due to toxicity | ||||
| raltegravir based | 1.33 (0.66–2.68) | 0.419 | 1.55 (0.69–3.50) | 0.286 |
| dolutegravir based | 1.00 | 1.00 | ||
| elvitegravir/cobicistat based | 1.43 (0.87–2.34) | 0.154 | 1.94 (1.00–3.76) | 0.051 |
Adjusted for age, gender, nation of birth, mode of HIV transmission, hepatitis coinfection status, AIDS diagnosis, baseline CD4 count, VL and year of starting cART.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
